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Abstract
Background: In multiple sclerosis, inflammatory cells are found in both active and chronic lesions, and it
is increasingly clear that cytokines are involved directly and indirectly in both formation and inhibition of
lesions. We propose that cytokine mixtures typical of Th1 or Th2 lymphocytes, or monocyte/
macrophages each induce unique molecular changes in glial cells.
Methods: To examine changes in gene expression that might occur in glial cells exposed to the secreted
products of immune cells, we have used gene array analysis to assess the early effects of different cytokine
mixtures on mixed CNS glia in culture. We compared the effects of cytokines typical of Th1 and Th2
lymphocytes and monocyte/macrophages (M/M) on CNS glia after 6 hours of treatment.
Results: In this paper we focus on changes with potential relevance for neuroprotection and axon/glial
interactions. Each mixture of cytokines induced a unique pattern of changes in genes for neurotrophins,
growth and maturation factors and related receptors; most notably an alternatively spliced form of trkC
was markedly downregulated by Th1 and M/M cytokines, while Th2 cytokines upregulated BDNF. Genes
for molecules of potential importance in axon/glial interactions, including cell adhesion molecules,
connexins, and some molecules traditionally associated with neurons showed significant changes, while no
genes for myelin-associated genes were regulated at this early time point. Unexpectedly, changes occurred
in several genes for proteins initially associated with retina, cancer or bone development, and not
previously reported in glial cells.
Conclusion: Each of the three cytokine mixtures induced specific changes in gene expression that could
be altered by pharmacologic strategies to promote protection of the central nervous system.
Published: 18 December 2007
Journal of Neuroinflammation 2007, 4:30 doi:10.1186/1742-2094-4-30
Received: 2 August 2007
Accepted: 18 December 2007
This article is available from: http://www.jneuroinflammation.com/content/4/1/30
© 2007 Lisak et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Journal of Neuroinflammation 2007, 4:30 http://www.jneuroinflammation.com/content/4/1/30
Page 2 of 20
(page number not for citation purposes)
Background
The pathogenesis of lesions in the central nervous system
(CNS) of patients with multiple sclerosis (MS) represents
the end product of several immune processes. Secretion of
cytokines by infiltrating inflammatory cells as well as by
endogenous glia contributes directly and indirectly to the
pathogenesis of the MS lesions [1,2]. Whether the initial
lesions in CNS white matter affect oligodendrocytes [3] or
activated microglia in normal appearing white matter
(NAWM) [4] is still not clear, but inflammatory cells are
part of active and chronic active lesions, the type I and II
lesions of Luchinnetti and Lassmann, as well as the type
III and type IV lesions, which are considered primarily
degenerative or toxic lesions of oligodendrocytes [5]. It is
also increasingly clear that cytokines are directly and indi-
rectly involved in inhibition of lesion formation.
There has been renewed interest in the pathologic changes
in axons in the white matter [6,7] as well as lesions in the
gray matter in patients with MS [8,9]. These changes,
which can be seen in the earliest lesions, have lead to the
view of MS as being, at least in part, a degenerative disease
of the CNS. Activated endogenous glia, particularly micro-
glia, and perhaps infiltrating inflammatory cells may also
contribute to the pathogenesis of lesions in other more
classically degenerative diseases of the CNS such as Alzhe-
imer's disease, Parkinson's disease and amyotrophic lat-
eral sclerosis (ALS). [10-13]. Since MS has a
neurodegenerative component and because much of the
permanent disability in MS results from axonal and neu-
ronal dysfunction, irreversible damage and cell loss
[14,15], there is increasing interest in treatments that are
able to attenuate neuronal damage and perhaps allow for
regeneration, so called "neuroprotection" [16-18]. Several
studies have emphasized the potential for the immune
system to provide neuroprotection and encourage repair
in experimental immunopathogenic disorders of the CNS
[19-21] and peripheral nervous system (PNS) [22] as well
as in traumatic [23,24] and degenerative diseases [25,26].
While much of the work on neuroprotection is in animal
models, there is some indirect evidence for neuroprotec-
tion provided by immunomodulatory therapy in patients
with MS [27-31]. In addition to protection of axons and
neurons and stimulation of regeneration of damaged
axons, it is naive to consider neurons and axons in isola-
tion from glial cells. Thus there is also a need to identify
factors that could inhibit demyelination and/or protect
oligodendrocytes and enhance oligodendrocyte precursor
maturation. Additionally the effects of cytokines, chemok-
ines and growth factors on astrocytes and microglia,
which undoubtedly play several roles in neuroprotection,
axonal outgrowth and synaptogenesis as well as develop-
ment of neurons, need consideration and study.
The development of MS lesions, as well as inhibition of
lesion formation and reparative processes, involves com-
plex interactions among mixtures of CNS cells. In addi-
tion single infiltrating inflammatory cells and glial cells
do not secrete single cytokines, and glial cells do not
respond by producing single growth factors or modifying
only one of their many cell functions. MS is a highly com-
plex disease with regards to basic immune and inflamma-
tory mechanisms involving the systemic immune system
as well the CNS. As such, complex techniques need to be
applied in MS research [32,33] so as to avoid oversimpli-
fication. For these reasons we have carried out a series of
experiments to examine the effects of different cytokine
mixtures, typical of Th1 and Th2 lymphocytes, as well as
monocyte/macrophages (M/M) on early gene expression
in mixed glial cell cultures. This approach also eliminates
the confounding effects of infiltrating inflammatory cells.
We chose to employ microarray technology, which allows
one to simultaneously examine the regulatory effect of
these mixtures of cytokines on a vast number of genes.
Thus one may not only see effects on a large number of
genes but may find regulatory effects on unanticipated
genes. To identify genes more likely to be directly affected
by the cytokine mixtures, we chose to start by examining
the effect on gene expression at 6 hours in vitro (early gene
expression).
Our rationale is to use genomics to identify the significant
early changes in gene expression in the interactive mixed
glial cell environment, with subsequent experiments
focused on identifying the specific cell types responsible
for those changes. Because of the large number of genes
regulated by these cytokine mixtures and issues of manu-
script length we reported the effects on genes of immune
system related molecules in an earlier separate report [34]
and divided other data into this paper with neuro-
trophins, other growth factors and structural proteins, and
a third paper looking at ion channels, neurotransmitters
and their receptors, mitochondria, signaling, transcription
factors, and molecules involved in apoptosis, among oth-
ers. In the first report we noted that expression of at least
814 genes of 7,985 analyzed were changed by a minimum
of 2 fold by one or more of the cytokine mixtures at 6
hours (early gene response) in vitro when compared to
control cultures. In this report and another paper in
progress, we present results of regulation of genes for mol-
ecules more classically related to glial and axonal/neuro-
nal cells. We are aware that the assignment of molecules
to one or the other such broad categories is arbitrary since
many of these molecules act in the immune system as well
as in the CNS. In addition, some molecules could be clas-
sified under any one of several categories in this report. As
examples, BIG-2 could be considered a neuronal protein
but is also an adhesion molecule; deleted in colon cancer
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(DCC) is a cancer-related protein but also a neuronal pro-
tein.
Methods
The methodology has been described in detail in the prior
paper [34].
Mixed CNS glial cell cultures
As described in the first report, mixed CNS glial cell cul-
tures were obtained from neonatal rat brain using a mod-
ification the so-called "shake-off" technique[35,36]. The
time for removal of microglia by adherence to plastic was
reduced to 1 hour prior to plating on poly-lysine coated
flasks following "shake-off". Cells were maintained in
defined medium containing 2% fetal bovine serum for
6–8 days, then treated with the cytokines. Culture compo-
sition was determined by employing indirect immunoflu-
orescence (IF) antibodies to phenotypic markers for
different cells types: glial acidic fibrillary protein (GFAP)
for astrocytes [37] (Chemicon, Temecula, CA); galactolip-
ids (GalL) for oligodendrocytes [37,38], A2B5 for oli-
godendrocyte precursors [39] (ATCC, Bethesda, MD); ED-
1 for microglia [40] (Serotec, Raleigh, NC); Th1.1 for
fibroblasts [41] and some astrocytes [42] (in glial cul-
tures), anti-neurofilament heavy (NFh) for neurons [43]
and anti-factor VIII for endothelial cells (Dako Corpora-
tion, Carpinteria, CA). To identify cells expressing major
histocompatibility complex class II molecules (MHC class
II) we employed mouse anti-MHC class II (Serotec).
Cytokine mixtures
Th1: Recombinant rat interleukin-2 (IL-2) and recom-
binant rat interferon-γ (IFN-γ) (R&D Systems, Inc, Minne-
apolis), recombinant rat tumor necrosis factor-α (TNF-α;
BD PharMingen, San Diego, CA) and recombinant rat
granulocyte-colony stimulating factor (G-CSF; PeproTech,
Rocky Hill, NJ).
M/M: Recombinant rat IL-1α and IL-1β, recombinant rat
IL-6, recombinant rat IL-12p40 (all from R&D Systems,
Inc) and recombinant rat TNF-α. These cytokines are con-
sidered to be proinflammatory products of what have
recently been termed M1 macrophages or microglia [44].
Th2: Recombinant rat IL-4, recombinant rat IL-5, recom-
binant rat IL-10 (all from R&D Systems, Inc), recom-
binant rat G-CSF and purified porcine transforming
growth factor-β1 (TGF-β1; R&D Systems, Inc). It has been
suggested that in the cognate immune system, TGF-β1 is
the product of a population of T-cells called regulatory T-
cells (Treg cells) and TGF-β is important in differentiation
of these Treg cells. Treg cells are phenotypically character-
ized as CD4+/CD25high+/Fox3 [45,46] and also secrete
IL-10 [47].
Cytokine mixtures contained 10 ng/ml of each of the con-
stituent cytokines as is typically employed in many in vitro
studies of cytokine biology and as employed by our group
[34]. Cultures were incubated with mixtures of Th1, Th2,
or M/M cytokines or additional medium (control) for 6
hours. Three separate experiments each consisting of con-
trol, Th1, M/M and Th2 stimulated cultures (a total of 12
cultures) were performed.
Cytotoxicity
Since certain cytokines have been reported to induce
death of oligodendrocytes and their precursors [48-50],
we examined the cytokine-induced effect on cell death in
mixed CNS glial cell cultures by incubating cultures from
6 hours to 4 days with the cytokine mixtures. Cell death
was determined by uptake of 0.4% trypan blue [51].
RNA extraction
After 6 hours of incubation with cytokine mixtures or
additional medium, cultures were washed and RNA was
extracted employing TRIzol (Gibco BRL, Grand Island,
NY) followed by Qiagen RNeasy kits (Qiagen, Valencia,
CA). The RNA was quantitated at A260 nm and the quality
was assessed by at A260 nm/A280 nm. The 28S/18S ratio was
assessed using a Bioanalyzer 2100 (Agilent Technologies,
Wilmington, DE) and was >1.7 for all samples.
Gene array analysis
Biotin-labeled RNA fragments were produced from 5 μg of
total RNA by first synthesizing double-stranded cDNA fol-
lowed by a transcription reaction and a fragmentation
reaction. A hybridization cocktail which contained frag-
mented cRNA, probe array controls (Affymetrix), bovine
serum albumin and herring sperm DNA was hybridized to
the Affymetrix rat RG-U34A microarray at 45°C for 16
hours. The probe array was then washed and bound
biotin-labeled cRNA detected with streptavidin phycoery-
thin conjugate. Subsequent signal amplification was per-
formed employing biotinylated anti-streptavidin
antibody. The RG-U34A chip contains 7,985 genes. Con-
trol and 3 cytokine-incubated cultures from one experi-
ment were analyzed with one gene chip for each sample
and three separate experiments using different cultures
were analyzed. The transcriptional profile data have been
submitted to the GEO repository, with accession number
GSE9659.
Data analysis
Gene array data were analyzed by several methods to
determine which genes were upregulated and downregu-
lated compared to control cultures for each series of cul-
tures, as well as comparing the average of the replicates
from each of the 3 separate sets of experiments. Affymetrix
data were analyzed with dChip v1.2 to calculate gene
expression values [52]. We analyzed values from 3 sepa-
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rate experiments employing the ANOVA GeneSpring, Agi-
lent Technologies, Santa Clara, CA) comparing Th1, M/M
and Th2 with control. While multiple testing analyses that
compare all 7,985 genes at different levels of stringency
using the Bonferoni and false discovery rate (FDR) at p <
0.05 are statistically most rigorous, at these high levels of
stringency, there were very few changes that reached statis-
tical significance. In order to increase sensitivity and allow
identification of potentially important biologic changes,
we employed a lower level of stringency. [34] While this
approach is likely to result in more false positive results, it
allows identification of gene changes in gene expression
and potentially protein expression that can later be veri-
fied by quantitative real time polymerase chain reaction
(QRT-PCR) and Western blotting respectively. In these
screening studies at a single time point, we have arbitrarily
chosen to represent as probably significant those genes in
which the mean expression was >2 fold (upregulation) or
<-2 fold (downregulation) compared to expression in
controls (p < 0.2) [34]. We believe this is reasonable given
that our experiments consisted of biological replicates
that are prone to greater variability than experimental rep-
licates. The recent literature suggests that a 2-fold cut-off
using the Affymetrix platform produces a low false posi-
tive rate [53].
Quantitative real time-polymerase chain reaction (QRT-
PCR) expression analysis
Expression of message for BDNF and NT3 was analyzed by
QRT-PCR on an ABI 7500 Fast System, using ABI Taqman
rat specific gene expression assays. RNA was extracted as
above and reverse transcribed. Relative expression levels
were calculated with GAPDH as the internal reference,
using the delta-delta Ct method [54]. The values from the
treated cultures were compared to those from control.
Those ratios were averaged for the three experiments, then
expressed as fold changes in the treated cultures relative to
control for comparison with the gene array results. Each
PCR value represents the average from 2–5 separate exper-
iments.
Results
Mixed CNS glial cell cultures
As described in our earlier report, cultures consisted of
approximately 35% each oligodendrocytes and astrocytes
and 10% microglia. The remaining cells were glial cell pre-
cursors including A2B5 oligodendrocyte precursors. There
were no endothelial cells or neurons. Viability was >98%
in both control and cytokine stimulated cultures at all
time points (6 hours to 5 days), demonstrating the lack of
cytotoxicity under these experimental conditions.
Overview of cytokine effects on early gene expression
Our previous paper [34] described changes in genes for
proteins predominantly associated with the immune sys-
tem including major histocompatibility molecules, some
adhesion and extracellular matrix molecules, cytokines
and chemokines and their receptors, complement compo-
nents and others. Because of our interests in the direct
effects of cytokines on endogenous CNS cells affecting the
production of factors important in oligodendrocyte
health and differentiation/myelination and axonal and
neuronal function, in this paper we compare the effects of
the different cytokine mixtures on gene expression of
genes associated with glial cells and neurons/axons. The
results are shown in Table 1 with changes in various cate-
gories summarized briefly below, but presented in more
detail in the Discussion.
Some of the gene classifications are arbitrary as many pro-
teins could be listed and considered under two or more
different categories. As noted, this is a series of screening
experiments and therefore the table and figures were pre-
pared using the criteria of > 2 fold (increased expression)
or <-2 fold (decreased expression) with a p value of <0.2
for one or two replicates of the gene transcript [34]. Values
for unidentified genes (EST) showing changes by these cri-
teria are not presented.
In view of the pleiotropic effects of the cytokine mixtures
on gene expression, we would predict changes in cellular
phenotype and function. Although these changes will be
examined in more detail in subsequent studies, two exam-
ples illustrating effects of the Th1 cytokine mixture on
microglia and oligodendrocyte precursors are shown in
Figures 1 and 2. By 4 days in vitro microglial cells have
changed their appearance when compared to unstimu-
lated cells and now expresses MHC class II on their sur-
face. Oligodendrocyte precursors still express A2B5 on
their surface but have begun to show much more elabo-
rate and extensive processes.
Neurotrophins and receptors
Th2 cytokines induced upregulation of the gene for brain
derived neurotrophic factor (BDNF), but in general the
cytokine mixtures had downregulatory effects on the
genes for neurotrophins and their receptors. The most
marked downregulation was found for an alternatively
spliced form of trkC with both Th1 and M/M cytokines.
(Table 1; -12 fold and -7 fold, respectively). For validation
of gene array results, expression of message for BDNF and
NT3 was analyzed by QRT-PCR. Results from the two
methods were in general agreement, with the exception of
Th2 effects on NT3 at 6 hours; subsequent QRT-PCR anal-
ysis at 24 hours showed a 3.44 fold upregulation, support-
ing the conclusion that Th2 increased the expression of
NT3 at 6 hours (Table 2).
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Table 1: Summary of changes in gene expression in neurotrophins, growth factors, related receptors and structural proteins
NEUROTROPHINS AND RECEPTORS Th1 M/M Th2
M55293 trkB -3.05* -2.7*
E03082 NT3 -4.15*** -2.71*** -4.73****
AI030286 brain derived neurotrophic factor -4.19*
AA944973 NGFR p75 precursor -4.26**
S62933 trkC, alternatively spliced -12.13*** -7.01***
AF023087 NGF-inducible IA 2.30*** 2.25*
X67108 brain derived neurotrophic factor 2.11*
M86742 pre-pro NT4 protein -2.62**
Y07559 NT 4/5 -2.63**
GROWTH/MATURATION FACTORS AND RECEPTORS
AI070577 insulin-like growth factor receptor 5 3.66**
Z14120 platelet-derived growth factor alpha (PDGF) 2.99**** 3.20*** 2.23***
M32167 vascular endothelial growth factor (VEGF) 2.39* 3.13**
D79215 fibroblast growth factor 10 2.17* 2.59*** 2.44*
M81183 insulin-like growth factor 1 (IGF-1) -2.02**
E0178 TGF-alpha -2.09**
M90660 insulin receptor-related receptor alpha -2.88**
X12748 epidermal growth factor precursor -3.48**** -2.53***
U37101 granulocyte colony stimulating factor 3 (GCSF) 3.24****
D10106 prepropeptide PDGF A chain 2.73*** 2.31***
D64085 fibroblast growth factor 5 2.18*
M18416 early growth response 1 2.03*
X07285 basic fibroblast growth factor -2.06*
U66470 cell growth regulatory with EF-hand domain -2.07*
AA818970 endothelin receptor type B 2.70****
AB008908 fibroblast growth factor 14 2.64*
AF014827 c-fos induced growth factor (VEGF D) 2.24**
S54008 fibroblast growth factor receptor 1 2.01***
U02320 neuregulin 1 -2.17**
AA875664 GCSF signaling molecule, mitochondria-associated -2.24****
M17960 insulin-like growth factor II (somatomedin A) -2.95**
AI137657 platelet-derived growth factor receptor alpha -3.04*
HORMONES, RECEPTORS AND RELATED MOLECULES
U94321 growth hormone secretagogue receptor 3.09* 3.13***
M54987 corticotropin releasing hormone 2.17* 2.40*
U55836 parathyroid hormone receptor -2.39**
U25803 luteinizing hormone, beta subunit -2.57*** -2.14** -2.18*
M34083 prolactin receptor -2.86*** -2.69***
M63296 luteinizing hormone receptor -2.92*
AA799498 natriuretic peptide precursor -3.09**
M27408 follicle stimuating hormone beta -3.21* -3.30*
Z33403 luteinizing hormone receptor -3.77** -2.80*
Z83757 growth hormone receptor -4.06* -3.81* -4.58*
Al235978 aldosterone receptor -6.13
S49003 short isoform growth hormone receptor 2.78*
U25802 luteinizing hormone, beta subunit -2.79***
L40030 placental growth factor -3.33**
X01454 thyroid stimulating hormone, beta subunit -3.55***
U41183 growth hormone releasing hormone -5.09*
M19304 prolactin receptor -5.81**
AA893618 glucocorticoid receptor -2.64*
U92469 gonadotropin-releasing hormone receptor -6.06**
AA946542 prolactin-like protein D -6.09*
Al180410 prolactin-like protein C -6.70***
CELL ADHESION AND EXTRACELLULAR MATRIX MOLECULES
S61868 syndecan 4 2.8* 3.5**
AA818894 proteoglycan core peptide 2.2*
U56859 perlecan -3.29*
S61868 syndecan 4 2.9*
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Growth and maturation factors and receptors
There are overlaps in classification of several proteins as
cytokines or growth factors, often considered as one or the
other depending on the effect being studied. Th1, M/M
and Th2 cytokine mixtures had complex and variable
effects on genes for many proteins in this category of mol-
ecules (Table 1). However there was no effect on glial
derived neurotrophic factor (GDNF) or GDNF family
members (neurturin, artemin or persephin) or their recep-
tors, although sequences for many of these genes are
present on the microarray chip we employed in these
experiments.
Hormones and hormone receptors
The different cytokine mixtures also had effects on some
genes for hormonal trophic and release factors and recep-
tors for these and other related hormones. Th1 and partic-
ularly M/M cytokines had both up and downregulatory
effects on several genes within this category whereas Th2
cytokines had more restricted effects (Table 1).
U16845 neurotrimin 2.76* 2.68*
U09401 tenascin c 3.92**
U15550 tenascin c 2.3*
Al071104 glypican 3 2.04**
MI5797 nidogen (entactin) -2.02*
D50568 proteoglycan, bone marrow -2.12*
AJ011811 claudin 7 -2.12*
U35371 BIG-2 -2.47**
X63143 syndecan 3 (neuroglycan) -2.44** -2.35**
AA8000059 syndecan 4 -2.9**
Al639167 biglycan (weakly similar to bone/cartilage p.g.) -3.57**
CONNEXINS
M76532 connexin 37 (CXN-37) 2.76**
M59936 connexin-31 (CXN-31) 2.03**
AF022136 connexin 40 (CXN-40) -2.82*
NEURONAL RELATED PROTEINS
M74223 VGF nerve growth factor inducible 3.04*** 3.79*** 2.25***
AF031430 syntaxin 7 2.09***
AF056704 synapsin 3 -2.18* -4.27***
S96418 activin receptor IIA -3.41*
U69702 activin receptor-like kinase 7 -3.62**
AA818677 neurofilament, heavy polypeptide -4.16*
Y16563 bassoon -4.88*
X17682 MAP 2 3.33**
U22952 neuroligin 2.49***
X66840 MAP 1A -2.07*
X06655 synaptophysin -2.13***
X06655 synaptophysin 2 -2.19****
M64488 synaptotagmin -2.20****
U71924 synaptotagmin XII -4.56*
AF041246 hypocretin (orexin) -5.88* -3.87***
L20820 syntaxin 3 -2.43***
X95286 semaphorin 3a -2.94***
RETINAL PROTEINS
X52376 rds/peripherin 2.09*** 2.15***
Z46957 rhodopsin -4.64*** -5.14**
CANCER RELATED PROTEINS
AF036760 breast cancer 1 -2.28* -2.52* -2.05*
U68725 deleted in colorectal cancer (rat homolog) -4.05**
U32081 deleted in malignant brain tumors 1 -6.02***
M32475 carcinoembryonic antigen -4.58*
BONE-RELATED PROTEINS
Y07704 Best 5 protein 39.49**** 7.02**
Y07704 Best 5 protein 31.46*** 7.41*
AA892798 USAG (uterine-sensitized associated gene 1) -2.10*
Values represent averages of fold changes from three separate experiments for each cytokine mixture compared to control. **** p < 0.01; *** p < 
0.05; ** p < 0.10; * p < 0.20
Table 1: Summary of changes in gene expression in neurotrophins, growth factors, related receptors and structural proteins (Continued)
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Cell adhesion and extracellular matrix molecules
In our initial paper, we noted changes in this class of mol-
ecules known to be involved in immune related interac-
tions. In the present paper, we present data on molecules
that may be involved in neuronal/glial interactions. Th1,
M/M cytokines as well as Th2 cytokines had regulatory
effects on a small number of genes for cell adhesion and
extracellular matrix (ECM) molecules including several
proteoglycans (Table 1).
Connexins
Th1 cytokines upregulated the genes for connexin 31 and
connexin 37, while M/M cytokines downregulated the
gene for connexin 40.
Myelin associated proteins
Although sequences of the genes specific for several mye-
lin associated proteins are present on the microarray chip,
we found no effects on genes for myelin-associated pro-
teins at 6 hours in vitro when compared to control cul-
tures.
Neuronal related proteins
Although there are no neurons in our cultures, we
observed cytokine-induced regulation of genes for neuro-
nal/axonal related proteins (Table 1). The genes for sev-
eral other proteins associated with neurons were regulated
by the different cytokine mixtures and are listed under
adhesion and extra-cellular matrix molecules. In a subse-
quent paper, we describe changes in genes for many ion
channels, peptides and transmitters and receptors associ-
ated with neurons but which are also known to be
expressed by glial cells.
Retinal proteins
M/M cytokines downregulated the gene for rhodopsin,
and Th2 cytokines upregulated the gene for rat retinal deg-
radation slow/peripherin 2 (rds/peripherin 2) (Table 1).
Cancer related proteins
We have noted an effect of the cytokines on expression for
genes for two proteins first described in cancer biology, rat
homologs for breast cancer 1 (BCR1), called BCRA1, and
deleted in colorectal cancer (DCC), both of which have
Effect of Th1 cytokines on microgliaFigure 1
Effect of Th1 cytokines on microglia. CNS mixed glial cultures were incubated with Th1 cytokines or additional culture 
medium for 4 days. Cultures were fixed with 4% paraformaldehyde for 10 minutes, washed and then incubated with mouse 
anti-ED-1 (IgM) and mouse anti-rat MHC class II (IgG) followed by Alexa 488-conjugated goat anti-mouse IgM and Cy 3-conju-
gated donkey anti-mouse IgG. Cultures were examined for indirect immunofluoresence employing a Leitz Orthoplan 2 fluores-
cent microscope. The Th1 treated microglia (ED-1+ cells) have a different appearance when compared to those incubated with 
additional medium (control). Control microglia do not express MHC class II whereas Th1 treated microglia strongly express 
MHC class II molecules.
Control
ED-1
Control
MHC-II
TH-1
ED-1
TH-1
MHC-II
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subsequently been reported to be present in neurons. In
addition there was marked downregulation by M/M
cytokines of the gene for carcinogenic embryonic antigen
(CEA), and marked downregulation by the Th2 cytokines
of a gene which is deleted in some gliomas. (Table 1)
Bone-related proteins
Th1 and M/M cytokines markedly upregulated the gene
for BEST 5, a protein involved in bone modeling, and Th2
cytokines downregulated uterine-sensitized associated
gene 1 (USAG1), a gene for an inhibitor of the bone mor-
phogenic protein family.
Discussion
Since the immune system seems capable of providing pro-
tection and promoting regeneration in the CNS and PNS,
it is reasonable to examine the roles of cytokines in these
reparative and protective processes. Cytokines themselves
may act directly as growth and development factors in the
nervous system [55,56], whether secreted by invading
Table 2: Effects of cytokines on BDNF and NT3 gene expression: comparison of gene array and QRT-PCR results
ACCESSION ID GENE TREATMENT FOLD CHANGE
6 hr array 6 hr PCR
Al030286, X67108 BDNF Th1 cytokines -4.19 -1.14
MM cytokines no change 1.09
Th2 cytokine 2.11 2.08
E03082 NT3 Th1 cytokines -4.15 -2.5
MM cytokines -2.71 -1.09
Th2 cytokines -4.73 2.13
CNS glial cultures were treated with the cytokine mixtures and analyzed by Affymetrix gene array or QRT-PCR, as described in Methods. The gene 
array values are the averages of 3 experiments; the QRT-PCR values are the averages of 3–5 experiments.
Effect of Th1 cytokines on oligodendrocyte precursorsFigure 2
Effect of Th1 cytokines on oligodendrocyte precursors. CNS mixed CNS glial cultures were incubated with Th1 
cytokines or additional medium and fixed as in Figure 1. Cultures were then incubated with mouse A2B5 (IgM) and mouse anti 
rat MHC class II (IgG) followed by Alexa 488-conjugated goat anti-mouse IgM and Cy 3-conjugated donkey anti-mouse IgG. 
Cultures were examined by indirect immunofluoresence as above. Compared to control, the Th1 treated A2B5+ oligodendro-
cyte precursors have a much more mature appearance including more extensive process formation although the cells still 
express A2B5, but do not express MHC class II.
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inflammatory cells or produced by endogenous glial cells.
In addition inflammatory/immune system cells secrete
classic neurotrophins and other factors that promote neu-
ronal and oligodendrocyte growth, developmental and
maintenance [57-59]. It has been known for many years
that some cytokines are able to induce secretion of neuro-
nal growth factors by endogenous cells of the CNS and
PNS [26,60,61]. Cytokine induction of growth factors,
including neurotrophins, by glial cells could serve as a
major source of such factors contributing to repair and
remyelination. Cytokines also likely induce oligodendro-
cyte and oligodendrocyte precursor cell damage and/or
inhibit recovery by down regulating growth factors and
their receptors. One would expect a differential effect of
different types of cytokines, in particular Th1 versus Th2
cytokines and perhaps cytokines associated with mono-
cytes/macrophages and microglia. This has been shown
for microglia [44,62]. In the following discussion we will
highlight some of the genes regulated and discuss the
implications of changes in the proteins specified by these
genes for MS as well as other neurologic diseases.
Recently, potential roles for both T regulatory (Treg) and
Th17 cells have been identified in EAE [63-68], and
cytokines secreted by these cells may also influence the
pathogenesis of lesions in multiple sclerosis [69,70] and
optical spinal multiple sclerosis [71]. The profile of these
cells under some conditions is partially known; for exam-
ple, Th17 cells secrete IFN-γ and the chemokine CCL20
[72]. More investigations will be needed to identify
whether the effects of cytokines secreted by the proinflam-
matory Th17 cells more closely resemble those of Th1
cells than of Th2 cells or macrophages [73,74].
Neurotrophins and receptors
With the exception of a 2-fold upregulation of the gene for
brain derived neurotrophic factor (BDNF) by Th2
cytokines, most of the genes for the neurotrophins and
their receptors were either downregulated by the different
cytokine mixtures or not affected in comparison to con-
trol cultures. In preliminary studies employing quantita-
tive real time polymerase chain reaction (QRT-PCR), we
have detected Th2 cytokine induced upregulation of the
gene for BDNF at both 6 and 24 hours. Although Th2
cytokines upregulated the gene for BDNF, they induced a
-2.6-fold downregulation of genes for pre-pro NT4/5, a
response potentially inhibitory for neuroprotection,
depending upon the timing of the downregulation and
the cell involved [75]. Downregulation of the genes for
BDNF, neurotrophin 3 (NT 3), trkB (receptor for BDNF as
well as for NT3), pre-pro NT 4/5, and an alternatively
spliced gene for trkC (receptor for NT3) by Th1 cytokines,
and of NT3 and trkC by M/M cytokines, if accompanied
by decreased levels of their proteins, would be detrimental
to neurons/axons and oligodendrocytes as well as inhibi-
tory to regeneration [76-80].
The gene for NGF-inducible protein 1A was interestingly
upregulated 2-fold by both M/M and Th2 cytokine mix-
tures. While inflammatory cells, including Th2 lym-
phocytes, produce neurotrophins [57,81,58,59],
cytokines produced by the same infiltrating cells, particu-
larly Th1 and M/M cells, could inhibit the production of
several of these neurotrophins by both the endogenous
glial cells and the infiltrating cells. Perhaps of equal
importance, these cytokine mixtures seem to downregu-
late the genes for receptors for several of these neuro-
trophins. BDNF and trkB have been detected in MS
lesions [82], while an increase in gene expression for NT3
and NGF2 has been reported in marginal zones of two
active lesions in MS [83]. The presence and concentration
of the different factors as well as the sequence of their
appearance may be important in neuroprotection and
remyelination. It is quite clear that more than one factor
is important for neuroprotection and regeneration as well
as for oligodendrocyte health and OPC maturation into
oligodendrocytes that are able to myelinate axons [84,85].
Both the combinations of neurotrophins as well as con-
centrations and timing of appearance and suppression of
the neurotrophins and their receptors are likely to be crit-
ical. In addition it is known that the effects of a particular
neurotrophin on a cell is in part determined by the bal-
ance of expression of its protein tyrosine kinase receptors,
such as trkB, and the low avidity p75 NGFR. [86,87] Th1
cytokines downregulated the gene for NGFR p75 precur-
sor protein, which not only binds all members of the NT
family and triggers cell death pathways, but also seems to
be involved in the common pathway signaling for Nogo,
myelin associated glycoprotein (MAG) and oligodendro-
cyte myelin glycoprotein (OmGp), in the inhibition of
neurite outgrowth by myelin [88].
Other growth and maturation factors and receptors
We observed changes in expression of a large number of
genes for neuropoietic cytokines [34] and for non-neuro-
trophin growth factors, important in different phases of
oligodendrocyte as well as neuronal/axonal development.
Some of these deserve comment as they may relate to
pathogenesis and recovery in MS and in other neurologi-
cal diseases.
Th1 cytokines induced downregulation of the gene for
TGF-α which signals via the epithelial growth factor recep-
tor (EGFR) [89], as well as down regulating the gene for
EGF precursor. Interestingly Th2 cytokines also downreg-
ulated expression of the gene for EGF precursor at 6 hours
in vitro (Table 1). TGF-α has been reported to be present
in astrocytes [90] and has effects on astrocyte function
[91,92] and development and function of neurons
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[89,93], as well as acting as a growth factor for tumors of
astrocyte [94] and non-CNS origin [95]. It seems to have
an antiapoptotic effect [92] and in combination with IFN-
γ upregulates cyclooxygenase2 (Cox 2) [96]. Thus Th1
cytokines, which include IFN-γ, by downregulating pro-
duction of TGF-α as well as EGF in inflammatory diseases
such as MS, would inhibit protection/development of cer-
tain neuronal populations. However, this same activity in
tumors would tend to inhibit tumor growth and survival.
EGF is critical in the development of the CNS, being one
of the more important growth factors for neuronal devel-
opment, acting on neural progenitor cells, as well as in
myelination [97-101].
Perhaps of equal importance is the down regulation of
bFGF (also called FGF2) by M/M cytokines, since this
growth factor appears important to some but perhaps not
all stages of neuronal and oligodendrocyte development
and protection [102,103,100,104-107]. FGF2 acts as a
mitogen for OPCs. Thus if M/M cytokines decreased
expression of FGF2, this would tend to inhibit OPC pro-
liferation. As noted later, some syndecans appear to bind
to FGF2. Upregulation of the gene for FGF2 has been
reported in some MS lesions [69] and FGFR-1 has been
reported present at the margins of chronic active and
chronic inactive lesions in MS [83]. There was also regula-
tion of the genes for other FGFs and receptors. EGF in
combination with bFGF is important in early stages of
neuronal and stem cell proliferation and later develop-
ment [108,109].
All three cytokine mixtures increased gene expression for
platelet-derived growth factor alpha (PDGF α) by 2 to 3-
fold, and M/M and Th2 cytokines similarly upregulated
the gene for prepropeptide PDGF A chain. Th2 cytokines
downregulated the gene for PDGF-Rα. At early stages of
OPC development, upregulation of PDGF-α and its recep-
tor would favor repair by serving as a mitogenic stimulus,
but persistent upregulation could inhibit ultimate matu-
ration and myelination, and downregulation of PGDF-Rα
at the correct time would favor transition from a precursor
stage to a more mature stage [110-112]. In addition PDGF
acts in concert with the chemokine Gro-α (CXCL1) to
induce OPC proliferation although persistence of these
two factors seems to prevent OPCs from undergoing fur-
ther maturation [113,114]. In our earlier report we
described Th1 cytokine upregulation of the gene for Gro-
α [34].
We observed effects of the cytokine mixtures on genes for
several other growth factors important for oligodendro-
cyte maturation and myelination as well as for neuronal
survival and development including neuregulin-1, insu-
lin-like growth factor (IGF-1) and one of its receptors/
binding proteins, IGF-R5 [115].
As with neurotrophins, downregulation of neuropoietic
cytokines and other growth factors could inhibit certain
phases of oligodendrocyte development and myelination,
as well as favor neurodegeneration. However, at other
stages inhibition of these same growth factors might be
necessary for OPC and neuronal maturation.
Neuregulins are a group of factors which are important in
CNS development, with multiple actions including pre-
cursor proliferation, cell migration, synaptogenesis and
control of certain aspects of myelination. Made in neu-
rons and perhaps in glia, neuregulins have the capacity to
bind to other cells in the nervous system and thus influ-
ence a large number of functions of several CNS cell types
[116-121]. We observed downregulation of the gene for
neuregulin type I induced by the Th2 cytokine mixture.
Lack of type II neuregulins (glial growth factor 2, GGF2)
has been reported in MS lesions by one group of investi-
gators [122] whereas another group found increased lev-
els when compared to non-MS white matter [123].
Insulin like growth factors (IGFs) are important in neuro-
nal and oligodendrocyte development [124-127]. There
are conflicting studies on the effects of IGF-1 on both the
clinical course and remyelination in animals with EAE
[128-131]. As summarized in the Table 1, Th1 cytokines
down regulated the gene for IGF-1 but upregulated the
gene for IGFR-5, one of several receptors for IGF-1. Th2
cytokines downregulated the gene for IGF-2 (somatome-
din), which can be found in CNS and PNS and may have
a protective role in inhibiting TNF-α-induced oli-
godendrocycte death [132,133].
Vascular endothelial growth factor (VEGF) is an impor-
tant factor in vascular biology particularly in angiogenesis
[134,135], and may have neurotrophic effects [136-138].
VEGF may contribute to inflammation within the CNS
and has been detected in acute and chronic active MS
plaques [139,140]. Th1 and Th2 cytokines both induced a
2 to 3-fold upregulation of the gene for VEGF.
Hormone and hormone receptors
Th1 and M/M cytokines induced upregulation of the
growth hormone secretagogue receptor, and both Th1 and
Th2 cytokines upregulated corticotrophin releasing hor-
mone, but in general Th1 and M/M cytokines had down-
regulatory effects on genes in this category. If the cytokines
had a similar effect on certain neuronal populations, these
findings might explain the overall downregulatory effect
of acute and chronic inflammation on normal endocrine
function and the increase in the corticosteroid response in
these same conditions. Prolactin regulates oligodendro-
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cyte precursor proliferation [141] and if downregulation
of the gene for prolactin receptor that we observed in
response to Th1 and M/M cytokines results in reduced
availability of receptor, there would be reduced ability of
such cells to develop and supply cells to replace injured
and dead oligodendrocytes as a source of remyelination.
Th2 cytokines induced downregulation of two different
prolactin-like proteins but not prolactin or its receptor.
Adhesion and extracellular matrix proteins
The cytokine mixtures had varying effects on the genes for
adhesion proteins and proteins associated with ECM,
including many arbitrarily classified as immune-molecule
related and reported in our earlier paper. Important
among those were several integrins and selectins, CD44
and several matrix metalloproteins [34]. In this study, we
observed changes in regulation of genes for several other
adhesion-related proteins that may be important in oli-
godendrocytes, oligodendrocyte precursor cells (OPCs),
neurons, axons as well as in axonal-glial interactions.
The proteoglycans are a group of glycoproteins with cova-
lently bound sulfated glycosaminoglycan (GAG) chains
which have been found in virtually all tissues and are
widely expressed on most cells types represented in the
CNS and PNS [142,143]. They are important in cell-cell
interactions as well as interactions of cells with the ECM.
The syndecans are proteoglycans and are type I transmem-
brane proteins with either heparan sulfate (HS) or chon-
droitin sulfate (CS) chains [142]. In our studies the
expression of syndecan-4 was upregulated by Th1 and M/
M cytokine mixtures, and downregulated by Th2
cytokines. Syndecan-4 has been found on various glial
cells and has a mix of HS and CS bound side
chains[142,144]. The ligands for syndecan 4 have not
been fully defined but other syndecans and possibly syn-
decan-4 are known to bind to several growth factor
including FGF2 [142,144] and TGF-β, as well as to ECM
molecules such as heparin-binding growth-associated
molecule (HB-GAM or pleiotrophin) and midkine [142].
In this study we demonstrated down regulation of the
gene for FGF2 at 6 hours in response to incubation with
M/M cytokines, upregulation of fibroblast growth factor
receptor-1 (FGFR-1) by Th2 cytokines (see below and
Table 1) and in our earlier report regulation of genes for
several binding and signaling molecules associated with
TGF-β by the different cytokine mixtures [34]. Syndecan -
1, the gene for which was not affected in our study, binds
to tenascin-C, an adhesion molecule. The gene for
tenascin-C was upregulated by Th2 cytokine mixtures. It
has been shown that TGF-β(a component of the Th2
cytokine mixture) and FGF2 upregulate tenascin-C [145].
Tenascin-C is one of a series of extracellular molecules
which bind to several proteoglycans including, as noted,
syndecan-1, as well as syndecan 3 (neuroglycan), a chon-
droitin sulfate proteoglycan. Syndecan-1 is found in sev-
eral organ systems; in the CNS syndecan-1 is likely a
neuronal membrane component while neuroglycan is
CNS specific, and expressed on neurons and astrocytes
[142]. Tenascin-C, which can bind to ng-CAM/Li and
NCAM on neurons [146], inhibits adhesion to collagen
[147], and is found in developing and injured CNS
[148,149]. It inhibits oligodendrocyte migration
[150,151] and inhibits axonal outgrowth [152]. Tenascin-
C knockout mouse embryos fail to develop normal cell
migration [153] emphasizing that normal development
requires a balance between positive and negative signals.
Finally tenascin-C, which is found in normal myelinated
tissue, is reduced in acute MS lesions and found in reactive
astrocytes in chronic lesions [154].
Glypicans, proteoglycans that are membrane bound,
essentially have only HS side chains. Glypican-3 is found
in the nervous system although its exact localization is not
clear. There is some evidence that it helps regulate activity
of insulin-like growth factor-II (IGF-II), perhaps by bind-
ing to IGF-II. Other cell surface molecules and ECM also
serve as ligands for glypican-3 [142]. A loss of function
mutation of glypican-3 is associated with Simpson-
Golabi-Behmel (SGB) syndrome, which has pre and post-
natal overgrowth and risk of embryonic tumors such as
Wilms tumors and neuroblastomas, the latter a tumor of
neuronal origin [155]. Interestingly over expression of
IGF-II has been associated with Beckwith-Wiedmann syn-
drome, a disorder similar to SGB [156,157]. We observed
upregulation of the gene for glypican 3 by mixtures of Th2
cytokines. As noted above, Th2 cytokines downregulated
the gene for IGF-II.
There is strong evidence, predominately in vitro, that pro-
teoglycans in their interactions with growth factors, ECM
and cell surface molecules are important in the regulation
of cell migration and proliferation in the CNS, as well as
neurite outgrowth and guidance and synaptogenesis. Pro-
teoglycans may be involved in inhibition of Schwann cell
entry into the CNS and inhibit neurite extension at the
damaged CNS/PNS interface [158], and inhibition of pro-
teoglycans allows improved recovery in a spinal cord
injury model [159]. Given the potential importance of
proteoglycans in the CNS, it is of interest that cytokine
mixtures differentially up- and downregulated the expres-
sion of genes for several of these proteoglycans and some
of their ligands.
We also observed cytokine regulation of several adhesion
molecules that are members of the immunoglobulin
superfamily. Neurotrimin is a neuronal adhesion mole-
cule that seems to inhibit axonal outgrowth, which is
important in development of CNS and sympathetic nerv-
ous system [160,161]. M/M and Th2 cytokine mixtures
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upregulated the gene for this protein, which at certain
stages of CNS disease such as MS might result in inhibi-
tion of neuronal regeneration, but at other stages could be
important in repair by helping direct appropriate connec-
tions.
The gene for contactin 4 (also called BIG-2), a member of
the TAG-1 subgroup of axon-associated cell adhesion
molecules (AxCAMs; members of the Ig superfamily), was
downregulated by Th2 cytokines [162]. Contactins, which
are expressed by neurons/axons and oligodendrocytes,
complex with a protein called contactin associated protein
(Caspr) and are found at paranodal regions of axon and
glial interaction [163]. Contactins are uniformly distrib-
uted along bare axons, and TAG1 is found at paranodes
with Caspr and is downregulated along myelinated axons
[164]. While there are no studies of the distribution of
contactins in MS lesions, there is a study of the distribu-
tion of Caspr on axons. Axons in the center of demyeli-
nated lesions do not express Caspr. Paranodal regions of
remyelinated axons express Caspr, and axons in border
zones of lesions express Caspr, but not in the normal par-
anodal pattern [165]. Contactin 4 is not known to directly
interact with Caspr and the exact nature of its ligand is not
clear. However it seems to be important in axonal/neurite
development [162,166].
We also detected Th2 cytokine downregulation of claudin
7, a member of the claudin family, tetraspan proteins
involved in tight junction formation. Claudin 7 is
expressed on CD4 T-lymphocytes, and downregulated in
tumor progression, but not previously identified in glia
[167,168]. Other claudins are expressed by endothelial
cells and choroid plexus epithelial cells [169,170], as well
as myelin forming cells and in myelin itself [171,172].
Connexins
Connexins are proteins that are part of gap junctions
between cells, which allow for direct communication
between these cells [173,174]. Some connexins are found
in glial cells and some seem to be important in myelina-
tion [175]. The genes for connexins 31 and 37 were upreg-
ulated by Th1 cytokines, and connexin 40 was
downregulated by M/M cytokines. Connexins 31 and 40
seem to be involved in pathways subserving hearing [176-
178].
Myelin associated proteins
At 6 hours, we did not detect any effect of the cytokine
mixtures on the genes for any myelin associated proteins
such as myelin basic protein (MBP), proteolipid protein
(PLP), myelin associated glycoprotein (MAG), oli-
godendrocyte myelin glycoprotein (OmGp) or claudin 11
(oligodendrocyte specific protein; Osp) although, as
noted, the genes for these proteins and other myelin asso-
ciated proteins are on the gene chips. This may relate to
the use of a 6 hour incubation, and follow-up studies
examining additional time points are clearly needed to
further investigate the effect of cytokines on the genes for
these proteins. It is known that IL-2 effects oligodendro-
cyte maturation and expression of MBP [55,179].
Neuronal related proteins
Although there are no neurons in our cultures, we
detected regulation of expression of genes for several
important proteins associated with neurons. Some have
already been discussed under other categories, including
adhesion molecules. Others that are known to be
expressed in glial cells as well as neurons, such as some of
the ion channels, transmitters and receptors, will be pre-
sented in a subsequent paper. In the following section, we
comment on genes for other proteins that may be of con-
siderable importance in the pathogenesis of several dis-
eases of the CNS, as well as in neuroprotection and repair
mechanisms.
Reduction in cerebrospinal fluid (CSF) levels of hypocre-
tin (orexin) are associated with classical narcolepsy [180]
as well as other disorders of sleep [181], and reduced
hypocretin positive neurons have also been described in
narcolepsy [182,183]. Hypocretin also seems to be
involved in energy metabolism and drinking behavior
[184,185]. Hypocretin containing neurons in the hypoth-
alamus have widespread projections in the CNS including
to the spinal cord [186,187] M/M cytokines downregu-
lated the gene for hypocretin receptor 2 (-5.9-fold), one of
two receptors for hypocretin, in glial cell cultures, as did
Th2 cytokines (Table 1). Levels of hypocretin itself have
been reported as normal in the CSF in most if not all stud-
ies of MS, but nothing is known about expression of
receptors for hypocretin in the CNS of patients with MS
[181,183]. If downregulation of hypocretin receptors in
neurons could be shown in vitro in response to cytokines
and in vivo, particularly in neurons of the hypothalamus
or reticular activating system, it might help in our under-
standing of fatigue and sleep disorders in MS patients.
Changes in genes for receptors for other transmitters such
as dopamine and serotonin, which we have noted in data
to be reported in a subsequent study, could also contrib-
ute to changes in mood, sleep and a sense of energy. In
our earlier paper we also described down regulation of the
gene for the gp130 receptor for leptin [34] which is not
only involved in appetite control and food intake but also
in energy metabolism. In addition, the widespread projec-
tions of the hypocretin neurons into other parts of the
brain and spinal cord could influence other CNS signs
and symptoms in MS including motor tone as well as sen-
sory and autonomic function.
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Th1 cytokines downregulated neurofilament heavy
polypeptide as did M/M cytokines. M/M cytokines down-
regulated the gene for MAP 1A (-2-fold), while Th2
cytokines upregulated the gene for MAP 2 (3-fold). MAP 1
and MAP 2 are associated with mature neurons [188,189],
although there is a report of expression of MAP 2 in oli-
godendrogliomas and glial precursor cells [190].
M/M cytokines down regulated the gene for synapto-
physin, a synaptic vesicle glycoprotein [191] as well as for
synaptotagmin 2, a calcium sensitive synaptic vesicle pro-
tein [192]. Th1 cytokines induced down regulation of the
gene for activin receptor-like kinase 7 (ALK7), part of a
family of receptor serine-threonine kinases (RSTK), which
interact with TGF-β superfamily members. To date ALK7
has been associated with neurons of the cerebellum, hip-
pocampus and brain stem nuclei [193]. Th1 cytokines
upregulated the gene for activin receptor interacting pro-
tein 1, also called synaptic scaffolding molecule (S-SCAM)
which resembles proteins that seem to be involved with
the assembly of receptors and cell adhesion proteins at
synaptic junctions [194,195]. M/M cytokines upregulated
the gene for neuroligin 1 which interacts with beta-neu-
rexins to help mediate synaptic development [196,197].
Th2 cytokines downregulated the genes for synapsin 3, a
synaptic vesicular protein inhibited by Ca2+ [198], as well
as semaphorin 3a; downregulation of this protein in MS
or other diseases by cytokines would have major implica-
tions for pathogenesis and repair since semaphorin 3
inhibits growth cones as a chemorepellant and may be an
important inhibitor of axonal regeneration and out-
growth. As a component of glial scars [199-202], sema-
phorin 3 could affect migration of neurons during
development [203,204], as well as glial migration
[205,206]. It may promote neuronal apoptosis [204]
including that in retinal ganglion cells following optic
nerve trauma [207], although interestingly it has also
been reported to protect neurons from activated microglia
[208]. In addition, production of semaphorin 3 by vascu-
lar endothelial cells inhibits vascular morphogenesis
[209]. Th2 downregulated the gene for semaphorin 3a,
which would favor axonal outgrowth.
Bassoon is a protein involved in synaptogenesis and in the
structure of the presynaptic active zone; its deletion causes
alterations in activation patterns and circuitry in the cor-
tex [210-212]. The gene for bassoon was down regulated
5-fold by Th1 cytokines (Table 1).
VGF, upregulated 2 to 4-fold by all three cytokine mix-
tures, is a neuronal secreted peptide stimulated by neuro-
trophic factors [213,214] and is upregulated in neuronal
development [215,216]. In addition to its role in neuro-
nal development and plasticity, it also has neuroeondo-
crine properties and helps regulate energy metabolism
[217].
It will be important to determine if these and other tradi-
tionally neuronal genes and their proteins are expressed in
glial cells, as well as to determine the effect of cytokine
mixtures on the genes and proteins of neurons since there
are significant implications for neuronal/axonal damage
as well as neuroprotection and inhibition of neuroprotec-
tive mechanisms due to changes in expression of these
proteins.
Retinal proteins
While there are no retinal ganglion cells or neurons in our
cultures, we found changes in two proteins important in
retinal diseases. Mutations in a human gene homologous
to rat rds/peripherin 2 have been reported associated in an
autosomal recessive inherited retinal disorder involving
pigmented epithelium [218]. The normal function of rds
is not known. Th2 cytokines upregulated the gene for rds/
peripherin 2 which might thus slow degeneration of reti-
nal cells in inflammatory or traumatic diseases if such Th2
cells were present in the retina. The gene for rhodopsin
(mutated in retinitis pigmentosa 4, autosomal dominant)
[219] is downregulated by M/M and Th2 cytokines, which
raises the question of the role of cytokines in inducing ret-
inal damage in inflammatory eye diseases.
Cancer related proteins
It is not known if BRCA1 and DCC are expressed in glial
cells and if so, their functions in glia are unknown. The
gene for the BRCA1 was downregulated by all three
cytokine mixtures. The rat homolog for the gene for the
human protein DCC was downregulated by Th1
cytokines. M/M down regulated a gene for what is now
still a theoretical protein, which is deleted in some glio-
mas. Th2 cytokines down regulated the gene for carci-
noembryonic antigen. It is not known if expression of
these gene and their products are affected by cytokines in
tumor cells. BRCA1 is a tumor suppressor protein and is
involved in DNA repair and cell growth. It is found in
embryonic and adult neural stem cells and seems linked
to proliferation [220]. DCC is a RAF kinase inhibitory pro-
tein (RKIF), previously called phosphtidylethanolamine
binding protein, which seems to have tumor suppressor
activity [221] and is deleted in several types of tumors,
including some colorectal cancers in humans [222]. In the
CNS it seems to play an important role in neuronal differ-
entiation, migration and determination of cell fate. [222]
DCC is the receptor for netrin-1 [223] and thus is impor-
tant for axonal guidance [188,224,225]. As the netrin-1
receptor, it also affects oligodendroglial and OPC migra-
tion, in general inhibiting migration [226,227], which is
the reverse of its usual effect on neuronal/axonal growth
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and migration. Netrins may also be involved in angiogen-
esis [228].
Bone related proteins
We observed dramatic upregulation of the gene for BEST
5 by Th1 and M/M cytokines, 40-fold and 7-fold respec-
tively. This factor has been reported to be upregulated in
osteoblasts by both type I and type II interferons with a
greater effect induced by type II IFN (IFN-γ). BEST 5 has
been found in bone where its functions include modeling
bone structure in response to physical stress [229]. To our
knowledge, this is the first description of either expression
or regulation of the gene for BEST 5 in cells of CNS origin.
M/M cytokines downregulated the gene for uterine sensi-
tization-associated gene protein 1. (USAG1). The protein
is a down regulator of the bone morphogenetic proteins
(BMP), which are members of the TGF-β superfamily and
found in the nervous system as well as being widely dis-
tributed in other organ systems. BMP are important in oli-
godendroglial, astrocyte and neuronal development
[230,231].
Conclusion
Gene expression studies in general and microarray studies
in particular have some limitations. Post-transcriptional
and post-translational changes are not detected and pro-
teins may already be present and involved in a biologic
process without requiring additional levels of protein and
no upregulation of the gene for that protein might occur.
However, as a screening technique to get an overview of
proteins that may be important in a particular process as
well as the complexities of the effect of a mixture of factors
on a mixture of cells, we believe that this is a promising
approach. In addition, microarray technology allows dis-
covery of unexpected findings in complex experiments.
Changes in gene expression detected with microarray
technology need to be confirmed using more quantitative
techniques and analysis of the effects of changes in gene
regulation on protein expression are a required next step.
Ultimately in vitro and in vivo experiments will be required
to determine the biological consequences of the changes
in gene expression described in these studies.
Comparison of the effects of the three cytokine mixtures
reveals a pattern of changes unique for each mixture, most
notably for the genes coding for growth/maturation fac-
tors, cell adhesion/ECM molecules and neuronal related
proteins. Thus, Th1 cytokines uniquely regulated IGF-1
and insulin-like growth factor receptor 5, M/M cytokines
regulated bFGF and FGF 5, while only Th2 cytokines reg-
ulated FGF 14, neuregulin 1, insulin-like growth factor II
and PDGF receptor alpha. Th2 cytokines regulated expres-
sion of a large number of genes for adhesion/ECM mole-
cules, while Th1 and M/M cytokines each uniquely
regulated a larger number of neuronal related proteins
than the Th2 cytokines. Further analysis of these patterns
of changes in comparison to those seen in the CNS of
patients with MS and EAE animals at various stages of dis-
ease and recovery promise to identify signaling networks
that could be directed by pharmacologic strategies to pro-
mote neuroprotection and regeneration.
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